WO2024121138 - CRYSTALLINE ADIPIC ACID SALT FORM OF A CCR6 ANTAGONIST
National phase entry:
Publication Number
WO/2024/121138
Publication Date
13.06.2024
International Application No.
PCT/EP2023/084328
International Filing Date
05.12.2023
Title **
[English]
CRYSTALLINE ADIPIC ACID SALT FORM OF A CCR6 ANTAGONIST
[French]
FORME DE SEL D'ACIDE ADIPIQUE CRISTALLIN D'UN ANTAGONISTE DE CCR6
Applicants **
IDORSIA PHARMACEUTICALS LTD
Inventors
FLEISCHER, Tony
MARCHAL, Daniel
RAGER, Timo
SCHAEFER, Gabriel
ZOUGGARI, Cécilia
Priority Data
PCT/EP2022/084559
06.12.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2040 | |
| EPO | Filing, Examination, Granting | 8126 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
19,732
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a crystalline form of 2-(3-{5-[(R)-(1,3-dimethyl-azetidin-3-yl)-hydroxy-(4-isopropyl- phenyl)-methyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol adipic acid salt and its use in the treatment or prevention of various diseases or disorders such as cancer or inflammatory/autoimmune diseases or disorders.[French]
La présente invention concerne une forme cristalline de sel d'acide adipique de 2-(3-5-[(R)-(1,3-diméthyl-azétidin-3-yl)-hydroxy-(4-isopropyl-phényl)-méthyl]-pyridin-3-yl}-[1,2,4]oxadiazol-5-yl)-propan-2-ol et son utilisation dans le traitement ou la prévention de maladies ou de troubles divers tels que le cancer ou de maladies ou de troubles inflammatoires/auto-immuns.